<DOC>
	<DOC>NCT02342314</DOC>
	<brief_summary>The study involves a single dose of LY3143753 or LY3185643, given as an injection into the abdomen. The study will evaluate the effects of the LY3143753 or LY3185643 on your body. The study is approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to the start of the study. This study involves Part A (LY3143753) and Part B (LY3185643). Participants may only enroll in one part and at one dose level.</brief_summary>
	<brief_title>A Study of LY3143753 and LY3185643 in Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Overtly healthy males or females Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures Are investigator site personnel directly affiliated with this study and their immediate families Are currently enrolled in a clinical trial involving an investigational product (IP) or offlabel use of a drug or device Have participated, within the last 3 months, in a clinical trial Have known or ongoing psychiatric disorders Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies Show evidence of hepatitis C and/or positive hepatitis C antibody Show evidence of hepatitis B and/or positive hepatitis B surface antigen History of/current phaeochromocytoma History of/current insulinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>